CJC-1295 DAC Peptide For Sale
CJC-1295 DAC research peptide for sale: 2mg, 5mg, 10mg and 20mg vial sizes. Sort: cost per month, price per vial or cost per mg with COAs to buy from USA sources.
Buy CJC 1295 Dac 5mg, 10mg or 2mg vials online with discount codes. CJC1295 for research purposes listed across multiple vendors to get the cheapest 5mg, 10mg or other vial size.
How much does CJC-1295 DAC cost per month?
An illustrative CJC-1295 DAC cost model works out to about $28.71 per month: Peptira's listed 5 mg purchase quantity at $33.15 with code WPA, divided into 1 mg amounts once weekly. This quantity provides 5.0 nominal portions — about 5.0 weeks at the selected cadence, before preparation losses or stability limits — for roughly $6.63 per week or $28.71 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 403 calculator runs; overall cadence comes from 87 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About CJC-1295 DAC
Pre-clinical / research-onlyAlso known as: CJC-1295 with DAC · DAC:GRFCJC-1295 with DAC is the long-acting GHRH-analog research peptide most often sourced for GH-axis protocols where a single weekly dose is preferred. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy CJC-1295 DAC:
- A third-party COA with mass-spec confirmation that the DAC linker is actually present — important because the DAC and no-DAC versions are easily confused, and they behave very differently.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill: a 5mg label should assay close to 5mg. Under-filled or mislabeled vials are a common failure mode, and they throw off every reconstitution calculation.
A Phase 1 single-ascending-dose study in healthy adults (Teichman et al., JCEM 2006) documented sustained ~1.5–3× elevation of IGF-1 lasting 6+ days after a single subcutaneous injection.[2] ConjuChem advanced CJC-1295 into Phase 2 trials for GH-deficient adults and pediatric short stature in 2007–2008; the program was halted following the death of a participant during a Phase 2 lipodystrophy trial.[3] No Phase 3 program followed and CJC-1295 has no active sponsor today.
Regulatory: Not FDA-approved. Clinical development halted after a 2008 Phase 2 safety event. Placed on the FDA 503A "do not compound" interest list in September 2023.
CJC-1295 DAC: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how CJC-1295 DAC works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
CJC-1295 DAC is a tetra-substituted analog of growth-hormone-releasing hormone (GHRH) residues 1–29 — the smallest fragment of natural GHRH that retains full receptor agonism — with four amino-acid substitutions added to resist enzymatic degradation and a maleimidopropionic-acid linker (ConjuChem's Drug Affinity Complex, or "DAC") attached at the Cys³⁴ position.[1] In circulation, the DAC linker forms a covalent bond with serum albumin's free cysteine residue, tethering the peptide to a long-lived carrier protein and extending the functional half-life from roughly 30 minutes (the no-DAC variant) to approximately 8 days.[2] The peptide still acts on the same target — the GHRH receptor on pituitary somatotropes — but instead of producing a brief, pulsatile signal it produces continuous receptor exposure. The downstream consequence is sustained 1.5–3× elevations in IGF-1 lasting six or more days after a single subcutaneous dose.[2] An important nuance: a follow-on study from the same Frohman group found that the pituitary still released GH in pulses on top of this continuous receptor stimulation, so it is more accurate to describe the pharmacology as raising the baseline GH "floor" than abolishing pulsatility outright.[4]
Active research areas
- Pulsatile vs. continuous GH signallingA central pharmacological question for any long-acting GHRH analog is whether continuous receptor stimulation changes the biology of GH/IGF-1 signalling in ways that pulsatile signalling does not — e.g. effects on body composition, insulin sensitivity, and somatotrope desensitization. Ionescu and Frohman showed pulsatility persists on top of CJC-1295 DAC,[4] which softens but does not fully answer the concern; this is the primary mechanistic reason clinicians who want to mimic physiological GH release prefer the no-DAC variant.
- Adult and pediatric GH deficiency (halted)ConjuChem advanced CJC-1295 into Phase 2 trials for adult GH-deficient patients and pediatric short stature in 2007–2008 on the strength of the sustained IGF-1 signal in healthy adults.[2] The program was discontinued in 2008 after the death of a participant in a Phase 2 lipodystrophy trial; no full clinical-trial publication followed, and no Phase 3 program was initiated. CJC-1295 has had no active pharmaceutical sponsor since.
- Lipodystrophy and metabolic indications (halted)The 2008 Phase 2 lipodystrophy trial was the program's nearest term metabolic indication — driven by the hypothesis that sustained GH/IGF-1 elevation would reverse the abnormal fat distribution seen in HIV-associated lipodystrophy. After the safety event halted CJC-1295 development, the lipodystrophy indication moved to tesamorelin (a different, shorter-acting GHRH analog), which subsequently won FDA approval in 2010.
- Off-label "research-peptide" useThe Sigalos and Pastuszak 2018 review in Sexual Medicine Reviews is one of the few peer-reviewed clinical sources that directly examines the safety/efficacy of growth-hormone secretagogues — including CJC-1295 — in the unregulated research-peptide market, noting that the published human evidence base for chronic dosing is essentially absent and that most "data" come from manufacturer claims and self-experimentation reports rather than controlled trials.[5]
- Regulatory status (FDA 503A interest list)In September 2023 the FDA placed CJC-1295 on the 503A "do not compound" interest list — the formal mechanism by which compounding pharmacies are barred from including a substance in patient-specific prescriptions. The listing cited insufficient safety information, unresolved questions about manufacturing quality, and the discontinued clinical-development history.[3]
Open questions & leading hypotheses (2)
- Hypothesis: Long-term continuous GHRH-receptor stimulation with CJC-1295 DAC is metabolically safe at "research-peptide" doses (typically 1–2 mg per week subcutaneous).Evidence: The Phase 1 single-dose data in healthy adults documented sustained IGF-1 elevation without acute safety signals,[2] and pulsatility persists on top of the continuous stimulation,[4] which weakens the "loss of pulse architecture" concern. Counter-evidence: the only Phase 2 chronic-dosing program was halted after a participant death in 2008, no full trial report was published, no Phase 3 data exist, and the Sigalos/Pastuszak review explicitly notes the absence of controlled chronic-dosing safety data for any GH secretagogue in the unregulated market.[5] The FDA's 2023 503A listing reflects this evidence gap.[3]
- Hypothesis: CJC-1295 DAC and CJC-1295 (no DAC) are functionally interchangeable at equivalent weekly cumulative doses.Evidence: Both molecules bind the same GHRH receptor and produce IGF-1 elevation; on a weekly cumulative basis the integrated GH/IGF-1 exposure can be matched.[1][2] Counter-evidence: the temporal pattern of exposure is fundamentally different — DAC produces a sustained "bleed" while the no-DAC variant produces a sharp pulse that decays within hours. Whether the body responds the same way to the same total exposure delivered in those two patterns is exactly the question Ionescu/Frohman started to address but did not definitively answer.[4]
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PeptideAdmin, CJC-1295 DAC users typically run 1–2 mg per week subcutaneous as a "set-and-forget" GH baseline raiser, often stacked with a ghrelin-receptor agonist (Ipamorelin or GHRP-2) injected separately to preserve pulse-like spikes on top of the DAC baseline.[6][7] The most common subjective reports are improved sleep quality (deeper, fewer wakings) and gradual recomposition over 8–12 weeks; the most common side-effect reports are water retention, transient numbness/tingling in the hands consistent with carpal-tunnel-style fluid effects from elevated GH, and a small cohort reporting fasting-glucose drift on long runs. A recurring discussion thread compares CJC-1295 DAC unfavourably to the no-DAC variant for users who specifically want to preserve pulsatile architecture and avoid sustained IGF-1 elevation. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what self-experimenters notice but do not establish that CJC-1295 DAC is safe or effective for any chronic indication — that question would require the kind of Phase 2/3 program that was halted in 2008 and has not been restarted.
Sources & references (7)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Jetté L et al. hGRF1-29-albumin bioconjugates activate the GHRH receptor and release GH and IGF-I in healthy male volunteers. Endocrinology 2005;146:3052–3058. · PMID: 15817669 link
- [2]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. JCEM 2006;91:799–805. · PMID: 16352683 link
- [3]FDA 503A Bulks List — CJC-1295 entry, September 2023. link
- [4]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. JCEM 2006;91:4792–4797. · PMID: 17018654 link
- [5]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018;6:45–53. · PMID: 28400207 link
- [6]Community report — r/Peptides CJC-1295 DAC vs. no-DAC discussion threads (subreddit), accessed May 2026. link
- [7]Community report — r/PeptideAdmin CJC-1295 DAC dosing and stacking discussions (subreddit), accessed May 2026. link
What CJC-1295 DAC Costs Right Now
WPA currently tracks CJC-1295 DAC from 6 distinct vendors across 7 separate CJC-1295 DAC listings. In-stock CJC-1295 DAC vials run from $33.15 to $431.55 — a 13x spread for the same compound. Peptira holds the lowest sticker price at $33.15. Normalized to milligrams, CJC-1295 DAC costs $6.63/mg to $21.58/mg on this page. The best per-milligram value is the listed 5 mg purchase quantity from Peptira.
CJC-1295 DAC is stocked in 4 sizes: 10 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 2 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the CJC-1295 DAC listings WPA tracks are: Peptira — 5mg at $33.15 ($6.63/mg), COA purity 99.77%; Paramount Peptides — 10mg at $92.86 ($9.29/mg), COA purity 99.12%; Omega — 5mg at $56.69 ($11.34/mg), COA purity 99.90%; Flawless Compounds — 5mg at $58.65 ($11.73/mg), COA purity 99.71%; Glow Aminos — 5mg at $58.65 ($11.73/mg), COA purity 99.71%.
CJC-1295 DAC COA Coverage Across Tracked Vendors
5 of the 7 tracked CJC-1295 DAC listings (71%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 5 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.12% to 99.90%. 5 listings record more CJC-1295 DAC in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 7/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the CJC-1295 DAC offer. WPA's listing fields do not establish that a report was independently verified.
CJC-1295 DAC Calculator Input Observations
In lifetime CJC-1295 DAC calculator inputs, 1mg is the most frequent entered amount (116 of 403 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (53 of 85 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1mg, Weekly (1x/wk) is most frequent (21 of 28 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 20 mg of listed product divided by 1 mg gives roughly 20 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
CJC-1295 DAC Discount Codes
7 of the 7 tracked CJC-1295 DAC listings carry a WPA researcher discount code. The largest live discount is 15% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About CJC-1295 DAC
CJC-1295 with DAC is the long-acting GHRH-analog research peptide most often sourced for GH-axis protocols where a single weekly dose is preferred. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
CJC-1295 DAC is tracked under the Muscle Peptides category on WPA. Its reported half-life is ~6–8 days. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
How to Read the CJC-1295 DAC Comparison
- Price per milligram — Every CJC-1295 DAC listing is normalized to $6.63/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 5 CJC-1295 DAC listings are marked for COA availability, and 5 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The CJC-1295 DAC comparison includes 2mg, 5mg, 10mg, and 20mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each CJC-1295 DAC listing, refreshed on a recurring basis.
Frequently Asked Questions: CJC-1295 DAC
Is it legal and safe to buy CJC-1295 DAC for research?
In the US, CJC-1295 DAC is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. It is a long-acting growth-hormone-releasing peptide with no approved human form, sold strictly for laboratory research. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 7 CJC-1295 DAC listings from 6 vendors.
How do I verify a CJC-1295 DAC COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific CJC-1295 DAC batch. Check that the report identifies the compound (actually CJC-1295 with DAC (the drug-affinity-complex version), not the shorter no-DAC variant or an underdosed vial), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For CJC-1295 DAC specifically, 5 of 7 tracked listings (71%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 5 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 7/26.
Which CJC-1295 DAC vendor should I pick?
There's no single "best" CJC-1295 DAC vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. The DAC modification is what gives this version its multi-day half-life, so favor vendors whose COA confirms the modified peptide rather than plain CJC-1295. 6 vendors currently carry CJC-1295 DAC, and Peptira holds the best true value at $6.63/mg on the 5 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does CJC-1295 DAC cost — and how do I know I'm not overpaying?
Judge CJC-1295 DAC by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It almost always ships in 5 mg vials, so compare $/mg across those rather than assuming the cheapest sticker price is the best value. Tracked CJC-1295 DAC listings currently run $6.63/mg to $21.58/mg across 2mg, 5mg, 10mg, 20mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much CJC-1295 DAC do I need for one full cycle?
In lifetime CJC-1295 DAC calculator inputs, 1mg is the most frequent entered amount (116 of 403 runs). Separately, Weekly (1x/wk) is the most frequent overall cadence (53 of 85 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1mg, Weekly (1x/wk) is most frequent (21 of 28 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 20 mg purchase quantity by 1 mg gives roughly 20 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for CJC-1295 DAC?
Participating CJC-1295 DAC vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 7 of the 7 tracked CJC-1295 DAC listings carry a code right now, the largest worth 15% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Lowest priced CJC-1295 DAC peptide for sale?
To surface the lowest priced CJC-1295 DAC for sale, WPA continuously compares 14 USA suppliers and 956 "for research" products, ranking every verified CJC-1295 DAC listing by true cost so the cheapest vials rise to the top. The lowest priced single CJC-1295 DAC vial currently starts at $33.15. We currently track 7 CJC-1295 DAC products in our system. Pricing is generally refreshed weekly as vendors update stock, prices, and discount codes.